KRAS突变型转移性结直肠癌治疗新进展：联合疗法展现良好耐受性与活性.pdfVIP

Cobimetinib+AtezolizumabWell

ToleratedandShowsPromising

ActivityinKRAS-MutantmCRC

CCOIndependentConferenceCoverage*

ofthe2016ASCOAnnualMeeting,June3-7,2016

*CCOisanindependentmedicaleducationcompanythatprovidesstate-of-the-artmedical

informationtohealthcareprofessionalsthroughconferencecoverageandothereducationalprograms.

ThisactivityissupportedbyeducationalgrantsfromAmgen,Ariad,

BayerHealthcarePharmaceuticals,CelgeneCorporation,Genentech,

Incyte,Merck,andTaihoPharmaceuticals.

Cobimetinib+AtezolizumabinKRAS-

MutantmCRC:Background

▪Chemotherapywithtargetedagentsstandardofcareforunresectable

mCRC[1]

▪MSI-HCRC,whichisDNAmismatchrepairdeficient,respondswell

toanti–PD-L1/PD-1inhibitors[2]

–However,mostmCRCsareMSSorDNAmismatchrepairproficient,

necessitatingadditionalnewtreatmentoptionsbeyondthePD-L1/PD-1

axis

▪MEKinhibitionsynergisticwithanti–PD-L1agents,promotingdurable

tumorregression[3]

▪StudyinvestigatedthecombinationofMEKinhibitor,cobimetinib,and

anti–PD-L1inhibitor,atezolizumab,inadvancedsolidtumors,

includingKRAS-mutantmCRC[4]

1.SeowHF,etal.OncoTargetsTher.2016;9:1899-1920.

2.LeDT,etal.NEnglJMed.2015;372:2509-2520.

3.EbertPJ,etal.Immunity.2016;44:609-621.

4.BendellJ,etal.ASCO2016.Abstract3502.Slidecredit:

Cobimetinib+AtezolizumabinKRAS-

MutantmCRC:StudyDesign

▪Open-labelphaseIbdoseescalationandexpansionstudy

3+3DoseEscalation

Ptswithchemo-refractory

†‡

solidtumors,ECOGPS0-1,Cobimetinib*20,40,or60mgPOQD+

measurablediseaseperAtezolizumab800mgIVQ2W